SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

G1 EXECUTION SERVICES, LLC

(Last)

(First)

(Middle)

175 W. JACKSON BLVD., SUITE 1700

501 PLAZA 2

(Street)

CHICAGO

60604

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/27/2020

3. Issuer Name and Ticker or Trading Symbol
ACHILLION PHARMACEUTICALS INC [ ACHN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10,917	D⁽¹⁾⁽³⁾
Common Stock	14,115,498	D⁽²⁾⁽³⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Call Option (right to buy)	⁽⁴⁾	12/18/2020	Common Stock	454,900	$7	D⁽²⁾⁽³⁾
Total Return Swap⁽⁵⁾	⁽⁶⁾	07/29/2020	Common Stock	8,000	⁽⁵⁾	D⁽³⁾
Total Return Swap⁽⁵⁾	⁽⁶⁾	07/30/2020	Common Stock	8,000	⁽⁵⁾	D⁽³⁾
Total Return Swap⁽⁵⁾	⁽⁶⁾	07/31/2020	Common Stock	8,000	⁽⁵⁾	D⁽³⁾
Total Return Swap⁽⁵⁾	⁽⁶⁾	08/03/2020	Common Stock	7,100	⁽⁵⁾	D⁽³⁾

1. Name and Address of Reporting Person^*

G1 EXECUTION SERVICES, LLC

(Last)

(First)

(Middle)

175 W. JACKSON BLVD., SUITE 1700

501 PLAZA 2

(Street)

CHICAGO

60604

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC

(Last)

(First)

(Middle)

401 CITY AVENUE, SUITE 220

(Street)

BALA CYNWYD

19004

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SUSQUEHANNA SECURITIES, LLC

(Last)

(First)

(Middle)

401 CITY AVENUE, SUITE 220

(Street)

BALA CYNWYD

19004

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. These securities are directly owned by G1 Execution Services, LLC ("G1X").

2. These securities are directly owned by Susquehanna Securities, LLC ("SS").

3. G1X, Susquehanna Fundamental Investments, LLC ("SFNDI") and SS are affiliated entities under common ownership. G1X, SFNDI and SS each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that any of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

4. These options are exercisable at any time prior to their expiration.

5. SFNDI has entered into cash-settled total return swaps with an unaffiliated third party financial institution, under which SFNDI acquired an aggregate of 31,100 "notional" shares of Achillion Pharmaceuticals, Inc. ("Achillion") common stock at prices ranging from $2.12 to $2.24 per share. The swap agreements provide that, upon settlement of the swaps, SFNDI will pay the applicable purchase price to the counterparty, and the counterparty will pay to SFNDI an amount equal to the then market price of the applicable number of shares of Achillion common stock. These swaps provide SFNDI with economic results that are comparable to the economic results of ownership of, but do not provide SFNDI with the power to vote or direct the voting of, or dispose of or direct the disposition of, the shares of common stock that are the subject of such swap.

6. Each of these total return swaps may be settled at any time prior to its expiration in SFNDI's discretion.

	G1 Execution Services, LLC By: /s/ Brian Sopinsky Name: Brian Sopinsky Title: Secretary	01/30/2020
	Susquehanna Fundamental Investments, LLC By: /s/ Brian Sopinsky Name: Brian Sopinsky Title: Assistant Secretary	01/30/2020
	Susquehanna Securities, LLC By: /s/ Brian Sopinsky Name: Brian Sopinsky Title: Secretary	01/30/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.